Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip S Pang

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Open Forum Infectious Diseases|August 14, 2023
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical TrialAdrienne E Shapiro, Elias Sarkis, Jude Acloque, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Gastroenterology|May 20, 2015
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseMichael Charlton, Gregory T Everson, Steven L Flamm, et al.
Nature Medicine|August 18, 2022
Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2Rachel J Hagey, Menashe Elazar, Edward A Pham, et al.
Lancet (London, England)|January 17, 2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyAnita Kohli, Anuoluwapo Osinusi, Zayani Sims, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Open Forum Infectious Diseases|August 14, 2023
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical TrialAdrienne E Shapiro, Elias Sarkis, Jude Acloque, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Gastroenterology|May 20, 2015
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseMichael Charlton, Gregory T Everson, Steven L Flamm, et al.
Nature Medicine|August 18, 2022
Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2Rachel J Hagey, Menashe Elazar, Edward A Pham, et al.
Lancet (London, England)|January 17, 2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyAnita Kohli, Anuoluwapo Osinusi, Zayani Sims, et al.
Pageof 5